Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.57 |
| ▸ | PDE4A | P27815 | 14/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PDE1A | P54750 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907670 | 0.88 | PDE4A (0.62) | MTNR1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3551313 | 0.79 | MTNR1A (0.67) | MTNR1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19559337 | 0.78 | MTNR1A (0.66) | MTNR1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18117796 | 0.78 | MTNR1A (0.66) | MTNR1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3546305 | 0.77 | MTNR1A (0.55) | MTNR1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18117787 | 0.77 | MTNR1A (0.64) | MTNR1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18117756 | 0.77 | MTNR1A (0.64) | MTNR1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19559348 | 0.77 | MTNR1A (0.64) | MTNR1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19559399 | 0.77 | MTNR1A (0.64) | MTNR1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3893558 | 0.75 | PDE4A (0.64) | MTNR1APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620083-A2 | COMBINATION THERAPIES | Pharmacia & Upjohn Company LLC (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1505972-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | Pharmacia Corporation (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004091596-A2 | COMBINATION THERAPIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209916-A1 | Combination therapies | PFIZER INC | 2004-10-21 | — | — | US | disclosed |
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | MANNING PAMELA T (US) | 2004-05-06 | — | — | US | disclosed |
| WO-2003097050-A2 | A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087653-A1 | Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor | NOS2, NOS1, PDE3A | MTNR1A 577/4885PDE4A 14/4885PDE4B 13/4885 |
| US-20040209916-A1 | Combination therapies | ADRA2C, ADRB2, ADRA2A | MTNR1A 31/4885PDE4A 17/4885PDE4B 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.